Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionGotham Asset Management, LLC
ManagerJoel Greenblatt
Latest Disclosed Ownership43,710 shares
Latest Disclosed Value $ 14,462,328
Gotham Asset Management, LLC reports 10.32% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Gotham Asset Management, LLC filed a 13F-HR form disclosing ownership of 43,710 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $12,487,947 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 39,622 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 10.32% during the quarter. The current value of the position is $11,386,455 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,710 4,088 10.32 14,462 -8.21 0.0443
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,622 11,487 40.83 15,756 22.81 0.0575
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,135 10,348 58.18 12,830 121.19 0.0559
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,787 3,270 22.53 5,800 48.00 0.0347
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,517 3,593 32.89 3,920 52.49 0.0327
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,924 -6,651 -37.84 2,571 -46.82 0.0244
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,575 4,338 32.77 4,834 50.28 0.0500
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,237 11,190 546.65 3,217 954.43 0.0416
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,047 -8,762 -81.06 306 -85.25 0.0046
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,809 7,727 250.71 2,069 279.45 0.0384
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,082 -775 -20.09 546 -25.55 0.0113
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,857 -1,259 -24.61 733 -28.52 0.0159
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,116 1,730 51.09 1,025 27.36 0.0248
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,386 3 0.09 805 18.76 0.0226
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,383 277 8.92 677 49.45 0.0203
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,106 1,808 139.29 453 113.68 0.0145
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,298 1,298 212 0.0066
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,464 -100.00 0 -100.00
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,464 1,544 52.88 486 44.64 0.0135
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,920 2,920 336 0.0062
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,499 -100.00 0 -100.00
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,499 -7,185 -74.19 294 -61.92 0.0043
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,684 9,684 772 0.0108
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.